Gossamer Bio Inc - Ordinary Shares

Gossamer Bio Inc - Ordinary Shares could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Gossamer Bio Inc - Ordinary Shares is not a good value stock. Gossamer Bio Inc - Ordinary Shares is not very popular among insiders. Tradey thinks it is not wise to invest in Gossamer Bio Inc - Ordinary Shares.
Log in to see more information.
Gossamer Bio, Inc. operates as a biopharmaceutical company, which focuses on discovering, acquiring,...
GOSS Fundamental Data by TradingView

News

Piper Sandler Keeps Their Buy Rating on Gossamer Bio (GOSS)
Piper Sandler Keeps Their Buy Rating on Gossamer Bio (GOSS)

TipRanks Financial Blog In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Gossamer Bio (GOSS - Research Report), with a price target...\n more…

Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss

Seeking Alpha - Long Ideas Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss...\n more…

Gossamer Bio, Inc. (NASDAQ:GOSS) to Post Q3 2024 Earnings of ($0.12) Per Share, HC Wainwright Forecasts
Gossamer Bio, Inc. (NASDAQ:GOSS) to Post Q3 2024 Earnings of ($0.12) Per Share, HC Wainwright Forecasts

Zolmax Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Analysts at HC Wainwright boosted their Q3 2024 earnings per share estimates for Gossamer Bio in a research report issued on Thursday, August 29th...\n more…

Research Analysts Issue Forecasts for Gossamer Bio, Inc.'s Q3 2024 Earnings (NASDAQ:GOSS)
Research Analysts Issue Forecasts for Gossamer Bio, Inc.'s Q3 2024 Earnings (NASDAQ:GOSS)

Ticker Report Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Equities researchers at HC Wainwright increased their Q3 2024 earnings per share (EPS) estimates for Gossamer Bio in a research report issued on...\n more…

Gossamer Bio announces data presentations at ERS Congress
Gossamer Bio announces data presentations at ERS Congress

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Business Wire Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...\n more…